The possible mechanisms of action of (-)deprenyl in Parkinson's disease J. Knoll OriginalPaper Pages: 177 - 198
The active centers of monoamine oxidase types “A” and “B”: Binding with (14C)-clorgyline and (14C)-deprenyl M. B. H. Youdim OriginalPaper Pages: 199 - 208
Absence of “cheese effect” during deprenyl therapy: Some recent studies M. SandlerVivette GloverG. M. Stern OriginalPaper Pages: 209 - 215
On the mode of action of L-deprenyl in the human central nervous system P. RiedererM. B. H. YoudimD. Seemann OriginalPaper Pages: 217 - 226
Recent observations on the clinical pharmacology of (-)deprenyl G. M. SternA. J. LeesM. Sandler OriginalPaper Pages: 245 - 251
L-deprenyl treatment of on-off phenomena in Parkinson's disease U. K. RinneT. SiirtolaV. Sonninen OriginalPaper Pages: 253 - 262
Experiences with L-deprenyl in Parkinsonism E. CsandaJ. AntalA. Csanaky OriginalPaper Pages: 263 - 269
Amphetamine and 2-phenylethylamine in post-mortem Parkinsonian brain after (-)deprenyl administration G. P. ReynoldsP. RiedererD. Seemann Short Communications Pages: 271 - 277
Anti-depressant potentiation of 5-hydroxytryptophan by L-deprenyl, an MAO “type B” inhibitor J. MendlewiczM. B. H. Youdim Short Communications Pages: 279 - 286